Alzheimer’s
Experts flag shingles vaccine, sildenafil and riluzole as leading Alzheimer’s repurposing candidates
Von KI berichtet Bild generiert von KI Fakten geprüft
A University of Exeter-led study funded by Alzheimer’s Society has identified three already-approved medicines—the shingles vaccine Zostavax, sildenafil (Viagra) and riluzole—as top “priority” candidates to be tested in clinical trials for Alzheimer’s disease, after a structured review of 80 existing drugs by an international expert panel.
A Cell Press review published on November 5, 2025, highlights tiny camelid-derived antibodies known as nanobodies as potential tools for treating conditions such as Alzheimer’s disease and schizophrenia. The authors say these proteins can reach brain targets in mice more readily than conventional antibodies and outline key steps before human testing.